FDA approves treatment for complicated UTI
The FDA has approved the combination of meropenem and vaborbactam (VABOMERE) for injection for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae—Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex. The combination therapy addresses gram-negative bacteria that produce beta-lactamase enzymes that have spread in the United States and Europe, particularly the Klebsiella pneumoniae carbapenemase enzyme. It is expected that the drug will be available in the fourth quarter of 2017, according to the Medicines Company.
For more information, go www.themedicinescompany.com/.